Tuesday, 1 November 2022

Rising Cancer Prevalence Leads to Significant Growth in the Liquid Biopsy Market

 One of the most important steps in treating or containing the disease is a timely and accurate diagnosis. The best chance of curing a disease is an early diagnosis, particularly in cases of cancer. The more advanced the cancer stage, the more painful the treatment will be, and the less likely the patient will survive. An early cancer diagnosis is essential for controlling the disease's progression and developing a successful treatment plan.



Cancer symptoms like fatigue, excruciating pain, swollen bumps, etc. typically show up in the later stages of the disease, when it has reached a dangerous stage. Therefore, doctors frequently advise routine cancer screenings, even for people who appear to be in good health.

Diagnosis is a distinct process from screening. It is used to hypothetically identify an undiagnosed disease in a population that appears healthy and asymptomatic using tests, examinations, or other techniques that are simple to use on the target population. A screening procedure includes the entire process, from inviting the target population to ensuring that those who are diagnosed with the disease can access effective treatment.

People are more susceptible to chronic diseases like cancer today because of the toxic environment and poor lifestyle choices. Therefore, the most effective defence against cancer is early diagnosis, prevention, and precaution.

The healthcare sector has benefited greatly from technological development. It has prompted the creation of more effective instruments and methods, significantly raising cancer patients' survival rates as a result.

Liquid biopsy is a non-invasive medical procedure that holds the ability to detect the presence of molecular cancer biomarkers in biological fluids. In this procedure, any non-tissue specimen, particularly body fluids such as blood, urine, stool, saliva, pleural fluid, and cerebral spinal fluid, is used to assess for tumors in the body. Several analytes, such as circulating tumor cells (CTCs), proteins, and circulating tumor DNAs (ctDNA), in the fluid are used to detect the tumor cell.

This procedure can eliminate the need for more expensive, invasive, and painful tumor tissue biopsies to enable dynamic tumor monitoring. Blood is the most common fluid used in liquid biopsy procedures for various types of cancers, while in the case of bladder tumors, urine is the best liquid biopsy component. Urine divided into two compartments can be useful for biomarker detection: supernatant and pellet. Supernatant biomarker consists of partially fragmented cell-free tumor nucleic acids and some other tumor-derived materials, while the pellet primarily consists of exfoliated normal and cancer cells, as well as immune cells, debris, and possible bacteria.

The liquid biopsy technique also plays a critical role in the precision medicine approach, as it confirms the safe and effective application of targeted therapeutics. It helps physicians to analyze tumor-related information through a simple blood test. Liquid biopsy can be used as a better alternative for treatment and recurrence monitoring as it overcomes invasive biopsy challenges of taking a tumor sample again and again during the treatment.

Owing to the increasing burden of cancer cases and increasing adoption of advanced technologies such as next-generation sequencing (NGS) and personalized medicine is leading to significant growth in the liquid biopsy market.

According to the BIS Research report, the global liquid biopsy market is projected to reach $19,066 million by 2032 from $2.58 billion in 2021 at a CAGR of 19.83% during the forecast period 2022-2032.

To get a free sample of the report, click here.

To combat the growing health crisis and cancer burden, self-awareness and preemptive checkups are crucial. Thankfully, a number of technological developments are proving to be very helpful in managing such chronic diseases. Future developments in diagnostic and therapeutic techniques are anticipated to revolutionize the healthcare industry.

Are you curious to learn more about the developing technologies in your industry's niche? Obtain the most recent market research and analysis from BIS Research. To learn more, get in touch with us at hello@bisresearch.com


BIS Related Studies

NGS Sample Preparation Market - A Global and Regional Analysis

Global Next-Generation Sequencing Market

Global NGS Informatics and Clinical Genomics Market



ABOUT BIS HEALTHCARE

 BIS healthcare vertical offers intelligence in the healthcare technology market for precision medicine, robotics and imaging, life sciences and biopharma, medical devices, digital health, and other emerging healthcare technologies, covering the entire industry spectrum. In the past eight years, BIS Healthcare has published more than 50 reports under the precision medicine banner. Additionally, BIS Research has been nominating ‘Top 25 Voices’ in precision medicine on its InsightMonk platform for the past two years successfully.





No comments:

Post a Comment

Growth in Global Female Technology Market

The growth of the Female Technology ( femtech) market indicates that the industry is on its way to breaking some of the existing barriers. ...